{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:24:22Z","timestamp":1760243062856,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:00:00Z","timestamp":1435190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Atherosclerosis is considered a generalized disease. Similar or identical etiopathogenetic mechanisms and risk factors are involved in various atherosclerotic diseases, and the positive effects of preventive measures on atherogenesis in different parts of the arterial system were shown. However, until know, great emphasis has been placed on the aggressive pharmacological management of coronary artery disease (CHD), while less attention has been devoted to the management of peripheral arterial disease (PAD), despite its significant morbidity and mortality. Data on the efficacy of preventive measures in PAD patients have mostly been gained from subgroup analyses from studies devoted primarily to the management of coronary patients. These data have shown that treatment of risk factors for atherosclerosis with drugs can reduce cardiovascular events also in patients with PAD. The effects of some preventive procedures in PAD patients differ from coronary patients. Aspirin as a basic antiplatelet drug has been shown to be less effective in PAD patients than in coronary patients. The latest Antithrombotic Trialists\u2019 Collaboration (ATC) meta-analysis demonstrates no benefit of aspirin in reducing cardiovascular events in PAD. Statins reduce cardiovascular events in all three of the most frequently presented cardiovascular diseases, including PAD to a comparable extent. Recent studies indicate that in PAD patients, in addition to a reduction in cardiovascular events, statins may have some hemodynamic effects. They prolong walking distance and improve quality of life. Similarly, angiotensin enzyme inhibitors are also effective in the prevention of cardiovascular events in coronary, cerebrovascular, as well as PAD patients and show positive effects on the walking capacity of patients with intermittent claudication.  In PAD patients, the treatment of hypertension and diabetes also effectively prevents cardiovascular morbidity and mortality. As PAD patients are at a highest risk of cardiovascular complications, the risk factors of atherosclerosis should be treated intensively in this group of patients. Most of the preventive measures, including the drugs used for prevention of CHD, are also effective in PAD patients.<\/jats:p>","DOI":"10.3390\/ijms160714477","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T10:17:15Z","timestamp":1435227435000},"page":"14477-14489","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?"],"prefix":"10.3390","volume":"16","author":[{"given":"Pavel","family":"Poredos","sequence":"first","affiliation":[{"name":"Department of Vascular Disease, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateja","family":"Jezovnik","sequence":"additional","affiliation":[{"name":"Department of Vascular Disease, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"97","article-title":"A clinical approach to the management of the patient with coronary (Co) and\/or carotid (Ca) artery disease who presents with leg ischaemia (Lis)","volume":"19","author":"Clement","year":"2000","journal-title":"Int. Angiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., and Kearney, P. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"ref_7","first-page":"274","article-title":"Does the preventive effect of different drugs depend on location of the atherosclerotic process?","volume":"27","author":"Poredos","year":"2008","journal-title":"Int. Angiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical aspects of platelet inhibitors and thrombus formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.thromres.2005.03.011","article-title":"Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease","volume":"117","author":"Kudoh","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1742-1241.2006.01063.x","article-title":"Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors","volume":"60","author":"Malinin","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2165\/11536000-000000000-00000","article-title":"Antiplatelet drugs\u2014Do we need new options?","volume":"70","author":"Coccheri","year":"2010","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2002). MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.arcmed.2006.12.012","article-title":"Statins and peripheral arterial disease: Effects on claudication, disease progression, and prevention of cardiovascular events","volume":"38","author":"Coppola","year":"2007","journal-title":"Arch. Med. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jvs.2007.03.035","article-title":"Statins: An essential component in the management of carotid artery disease","volume":"46","author":"Paraskevas","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366, 1267\u20131278.","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0002-9149(02)02616-4","article-title":"Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg\/dL treated with statins versus no lipid-lowering drug","volume":"90","author":"Aronow","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"(1984). The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA, 251, 351\u2013364.","DOI":"10.1001\/jama.251.3.351"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jvs.2011.08.044","article-title":"Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia","volume":"55","author":"Aiello","year":"2012","journal-title":"J. Vasc. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: Insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jacc.2013.09.073","article-title":"Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia","volume":"63","author":"Westin","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejvs.2006.03.009","article-title":"Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?","volume":"32","author":"Paraskevas","year":"2006","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","article-title":"Fluvastatin and perioperative events in patients undergoing vascular surgery","volume":"361","author":"Schouten","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.jhh.1001209","article-title":"Peripheral vascular disease and hypertension: A forgotten association?","volume":"15","author":"Makin","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1532-5415.1985.tb02853.x","article-title":"Update on some epidemiologic features of intermittent claudication: The Framingham Study","volume":"33","author":"Kannel","year":"1985","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0895-4356(94)90128-7","article-title":"A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968\u20131986: A strong relationship to smoking and serum cholesterol\u2014The Reykjavik Study","volume":"47","author":"Ingolfsson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"SHEP Cooperative Research Group (1991). Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265, 3255\u20133264.","DOI":"10.1001\/jama.265.24.3255"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.CIR.0000049640.46039.52","article-title":"Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes","volume":"107","author":"Mehler","year":"2003","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"The Treatment of Mild Hypertension Research Group (1991). The treatment of mild hypertension study: A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch. Intern. Med., 151, 1413\u20131423.","DOI":"10.1001\/archinte.151.7.1413"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"ALLHAT Collaborative Research Group (2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 283, 1967\u20131975.","DOI":"10.1001\/jama.283.15.1967"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.1991.00400090063012","article-title":"\u03b2-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials","volume":"151","author":"Radack","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Guidelines Committee (2003). 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens., 21, 1011\u20131053.","DOI":"10.1097\/00004872-200306000-00001"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.amjcard.2006.05.039","article-title":"Effect of \u03b2 blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction","volume":"98","author":"Kopecky","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.2165\/00003495-200262090-00016","article-title":"Ramipril: A review of its use in the prevention of cardiovascular outcomes","volume":"62","author":"Warner","year":"2002","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"Ostergren","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"(2003). The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362, 782\u2013788.","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.2012.216237","article-title":"Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial","volume":"309","author":"Ahimastos","year":"2013","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc06-0013","article-title":"Point: Impaired fasting glucose: The case for the new American Diabetes Association criterion","volume":"29","author":"Shaw","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group (2000). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med., 342, 381\u2013389.","DOI":"10.1056\/NEJM200002103420603"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1464-5491.2010.03153.x","article-title":"Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry","volume":"28","author":"Camafort","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"CTDR Group (1995). \u00a0Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol., 75, 894\u2013903.","DOI":"10.1016\/S0002-9149(99)80683-3"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/diacare.29.04.06.dc05-2018","article-title":"HbA1c and peripheral arterial disease in diabetes: The Atherosclerosis Risk in Communities Study","volume":"29","author":"Selvin","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2362.2007.01747.x","article-title":"Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease","volume":"37","author":"Maca","year":"2007","journal-title":"Eur. J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/7\/14477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:48:21Z","timestamp":1760215701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/7\/14477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["ijms160714477"],"URL":"https:\/\/doi.org\/10.3390\/ijms160714477","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2015,6,25]]}}}